Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris

What Brokers Say Health Written by: Ian Lyall 10:15 Fri 28 Aug 2026 --> Edited by: Ian Lyall Disclaimer No investment advice About this content Editorial Standards & Policies Share article About this content × About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business output at the Daily... Read more About the publisher Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists. Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. Use of technology Proactive has always been a forward looking and enthusiastic technology adopter. Our human content creators are equipped with many decades of valuable expertise and experience. The team also has access to and use technologies to assist and enhance workflows. Proactive will on occasion use automation and software tools, including generative AI. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation. Shield Therapeutics PLC ( AIM:STX OTCQB:SHIEF ) View Price & Profile Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris Published: 10:15 28 Aug 2026 BST Cavendish has reiterated its buy rating on Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) following the pharmaceutical company's agreement to take full commercial control of its main United States (US) product from Viatris. The broker kept its target price at 23 pence, implying potential upside of 318% from current share price of about 5.5 pence. Shield, which is listed on London's AIM market, announced on Thursday that it would assume full responsibility for ACCRUFeR, an oral iron replacement therapy, in the US from 30 September. The company will take over commercial operations without making any upfront cash payment. Instead, Shield will pay Viatris a reduced royalty on US net sales, ranging from high single digits to the mid-teens, over five years. Cavendish called the deal one of the most significant strategic developments for Shield since its original US agreement in 2022. The broker said bringing the sales team in-house should improve profit margins, even as operating costs rise. Shield's management expects the transaction to be immediately value accretive to the business. Cavendish forecasts Shield's revenue will rise to £78.7 million in the 2026 financial year, up from £49.7 million in 2025. Continue reading